RDY Stock Recent News

RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.

Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q1 2026 Earnings Conference Call July 23, 2025 10:00 AM ET Company Participants Erez Israeli - CEO & Member of the Management Council Mannam Venkatanarasimham - CFO & Member of the Management Council Richa Periwal - Head of Investor Relations and Analytics Conference Call Participants Abdulkader Puranwala - ICICI Securities Limited, Research Division Aman Vij - Unidentified Company Amey Chalke - JM Financial Institutional Securities Limited, Research Division Bino Joseph Pathiparampil - Elara Securities (India) Private Limited, Research Division Damayanti Kerai - HSBC Global Investment Research Foram Prashant Parekh - BOB Capital Markets Limited, Research Division Harith Mohammed Ahamed - Spark Institutional Equities Private Limited, Research Division Kunal Dhamesha - Macquarie Research Madhav Marda - Unidentified Company Fidelity Investments - Unidentified Company Neha Manpuria - BofA Securities, Research Division Saion Mukherjee - Nomura S

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #ConsolidatedFinancialResults--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2025.

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on Wednesday.

ACHC, CNL and RDY have been added to the Zacks Rank #5 (Strong Sell) List on July 18, 2025.

Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.

HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #Alvotech--Alvotech and Dr. Reddy's Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).

I reiterate my strong buy rating on Dr. Reddy's Laboratories due to its attractive valuation and underappreciated growth potential beyond Revlimid. Recent results exceeded expectations, with 20% YoY revenue growth driven by acquisitions and strong performance in generics, especially in Europe and India. While Revlimid's patent expiry poses a headwind, RDY's robust pipeline in biosimilars and GLP-1s should offset revenue declines and support long-term growth.

Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.

Erez Israeli, CEO of Dr. Reddy's, discusses the potential impact of Trump's proposed drug pricing changes, noting that "generics normally give significant discounts," and shares how the company plans to expand its diabetes and obesity drug offerings amid increasing competition.